Acquisition by Nelson Cabatuan of 65325 shares of Rain Therapeutics subject to Rule 16b-3
RAINDelisted Stock | USD 1.41 0.01 0.70% |
About 62% of Rain Therapeutics' investor base is looking to short. The analysis of current outlook of investing in Rain Therapeutics suggests that many traders are alarmed regarding Rain Therapeutics' prospects. Rain Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in Rain Therapeutics. Many technical investors use Rain Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Rain |
Filed transaction by Rain Oncology Inc officer. Grant, award or other acquisition pursuant to Rule 16b-3(d)
Read at macroaxis.com
Rain Therapeutics Fundamental Analysis
We analyze Rain Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Rain Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Rain Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Income
Net Income Comparative Analysis
Rain Therapeutics is currently under evaluation in net income category among its peers. Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Rain Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Rain Therapeutics stock to make a market-neutral strategy. Peer analysis of Rain Therapeutics could also be used in its relative valuation, which is a method of valuing Rain Therapeutics by comparing valuation metrics with similar companies.
Peers
Rain Therapeutics Related Equities
OCEA | Ocean Biomedical | 1.41 | ||||
ELEV | Elevation Oncology | 1.64 | ||||
ENVB | Enveric Biosciences | 2.94 | ||||
HEPA | Hepion Pharmaceuticals | 4.35 | ||||
ZURA | Zura Bio | 6.83 |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Other Consideration for investing in Rain Stock
If you are still planning to invest in Rain Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Rain Therapeutics' history and understand the potential risks before investing.
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |